Skip to main content
SpringerLink
Log in
Book cover

Renal Cancer pp 411–435Cite as

Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma

  • Chapter
  • First Online:

  • 658 Accesses

Abstract

Renal cell carcinoma (RCC) remains a significant cause of mortality among genitourinary malignancies. It will be essential to rationally integrate surgery and systemic therapy to improve outcomes in RCC. Despite substantial efforts to date and a newly FDA-approved agent, there remains no clear role for adjuvant therapy following nephrectomy for clinically localized disease. Several studies aimed to identify effective agents in the adjuvant setting, including mTOR and tyrosine kinase inhibitors, vaccines, as well as a monoclonal antibody against CA IX. None have shown improvement in overall survival. Sunitinib has had mixed results and may improve disease-free survival in a high-risk subset. For locally advanced disease, it has been proposed that neoadjuvant therapy may make unresectable disease resectable, enable partial nephrectomy, or shrink venous tumor thrombus. These theoretical goals remain in need of further study. For patients with metastatic RCC, the correct paradigm remains to be elucidated. In particular, the role of cytoreductive nephrectomy in the modern era is an active area of debate and research.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Cronin KA, Lake AJ, Scott S, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2018;124(13):2785–800.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Bex A, Jonasch E, Kirkali Z, et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol. 2010;58(6):819–28.

    Article  PubMed  Google Scholar 

  3. Jacobsohn KM, Wood CG. Adjuvant therapy for renal cell carcinoma. Semin Oncol. 2006;33(5):576–82.

    Article  CAS  PubMed  Google Scholar 

  4. Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res. 2007;13(2 Pt 2):697s–702s.

    Article  PubMed  Google Scholar 

  5. Cindolo L, de la Taille A, Messina G, et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int. 2003;92(9):901–5.

    Article  CAS  PubMed  Google Scholar 

  6. Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol. 2008;179(6):2146–51; discussion 2151.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Yaycioglu O, Roberts WW, Chan T, Epstein JI, Marshall FF, Kavoussi LR. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology. 2001;58(2):141–5.

    Article  CAS  PubMed  Google Scholar 

  8. Smaldone MC, Fung C, Uzzo RG, Haas NB. Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma. Hematol Oncol Clin North Am. 2011;25(4):765–91.

    Article  PubMed  Google Scholar 

  9. Lane BR, Kattan MW. Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am. 2008;35(4):613–25; vii.

    Article  PubMed  Google Scholar 

  10. Cindolo L, Patard JJ, Chiodini P, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer. 2005;104(7):1362–71.

    Article  PubMed  Google Scholar 

  11. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166(1):63–7.

    Article  CAS  PubMed  Google Scholar 

  12. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005;173(1):48–51.

    Article  PubMed  Google Scholar 

  13. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97(7):1663–71.

    Article  PubMed  Google Scholar 

  14. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20(23):4559–66.

    Article  PubMed  Google Scholar 

  15. Kenney PA, Wood CG. Integration of surgery and systemic therapy for renal cell carcinoma. Urol Clin North Am. 2012;39(2):211–31, vii.

    Article  PubMed  Google Scholar 

  16. Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer. 2008;113(3):450–60.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998;159(4):1163–7.

    Article  CAS  PubMed  Google Scholar 

  18. Klatte T, Lam JS, Shuch B, Belldegrun AS, Pantuck AJ. Surveillance for renal cell carcinoma: why and how? When and how often? Urol Oncol. 2008;26(5):550–4.

    Article  PubMed  Google Scholar 

  19. Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22(16):3316–22.

    Article  Google Scholar 

  20. Kim HL, Seligson D, Liu X, et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 2004;10(16):5464–71.

    Article  CAS  PubMed  Google Scholar 

  21. Klatte T, Seligson DB, LaRochelle J, et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomark Prev. 2009;18(3):894–900.

    Article  CAS  Google Scholar 

  22. Parker AS, Leibovich BC, Lohse CM, et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer. 2009;115(10):2092–103.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Choueiri M, Tannir N, Jonasch E. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr Clin Pharmacol. 2011;6(3):144–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Aref I, Bociek RG, Salhani D. Is post-operative radiation for renal cell carcinoma justified? Radiother Oncol. 1997;43(2):155–7.

    Article  CAS  PubMed  Google Scholar 

  25. Finney R. The value of radiotherapy in the treatment of hypernephroma--a clinical trial. Br J Urol. 1973;45(3):258–69.

    Article  CAS  PubMed  Google Scholar 

  26. Kjaer M, Iversen P, Hvidt V, et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol. 1987;21(4):285–9.

    Article  CAS  PubMed  Google Scholar 

  27. Hallemeier CL, Choo R, Davis BJ, et al. Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1938–43.

    Article  PubMed  Google Scholar 

  28. Ulutin HC, Aksu G, Fayda M, Kuzhan O, Tahmaz L, Beyzadeoglu M. The value of postoperative radiotherapy in renal cell carcinoma: a single-institution experience. Tumori. 2006;92(3):202–6.

    Article  PubMed  Google Scholar 

  29. Lam JS, Belldegrun AS, Figlin RA. Adjuvant treatment for renal cell carcinoma. Expert Opin Pharmacother. 2006;7(6):705–20.

    Article  CAS  PubMed  Google Scholar 

  30. Pizzocaro G, Piva L, Di Fronzo G, et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol. 1987;138(6):1379–81.

    Article  CAS  PubMed  Google Scholar 

  31. Naito S, Kumazawa J, Omoto T, et al. Postoperative UFT adjuvant and the risk factors for recurrence in renal cell carcinoma: a long-term follow-up study. Kyushu University Urological Oncology Group. Int J Urol. 1997;4(1):8–12.

    Article  CAS  PubMed  Google Scholar 

  32. Fujikawa K, Matsui Y, Miura K, et al. Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy. J Urol. 2000;164(3 Pt 1):673–5.

    Article  CAS  PubMed  Google Scholar 

  33. Dadian G, Riches PG, Henderson DC, et al. Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy. Br J Urol. 1994;74(1):15–22.

    Article  CAS  PubMed  Google Scholar 

  34. Montie JE, Straffon RA, Deodhar SD, Barna B. In vitro assessment of cell-mediated immunity in patients with renal cell carcinoma. J Urol. 1976;115(3):239–42.

    Article  CAS  PubMed  Google Scholar 

  35. Rayman P, Wesa AK, Richmond AL, et al. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res. 2004;10(18 Pt 2):6360S–6S.

    Article  CAS  Google Scholar 

  36. Arya M, Chao D, Patel HR. Allogeneic hematopoietic stem-cell transplantation: the next generation of therapy for metastatic renal cell cancer. Nat Clin Pract Oncol. 2004;1(1):32–8.

    Article  PubMed  Google Scholar 

  37. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23(1):133–41.

    Article  CAS  PubMed  Google Scholar 

  38. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol. 2005;23(3):202–12.

    Article  CAS  Google Scholar 

  39. Shimabukuro T, Naito K. Tumor-infiltrating lymphocytes derived from human renal cell carcinoma: clonal analysis of its characteristics. Int J Urol. 2008;15(3):241–4.

    Article  PubMed  Google Scholar 

  40. Kradin RL, Kurnick JT, Lazarus DS, et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet. 1989;1(8638):577–80.

    Article  CAS  PubMed  Google Scholar 

  41. Finke JH, Tubbs R, Connelly B, Pontes E, Montie J. Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma. Ann N Y Acad Sci. 1988;532:387–94.

    Article  CAS  PubMed  Google Scholar 

  42. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol. 1992;148(4):1247–8.

    Article  CAS  PubMed  Google Scholar 

  43. Sanchez-Ortiz RF, Tannir N, Ahrar K, Wood CG. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine? J Urol. 2003;170(1):178–9.

    Article  PubMed  Google Scholar 

  44. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet. 1999;353(9146):14–17.

    Google Scholar 

  45. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17(9):2859–67.

    Article  CAS  PubMed  Google Scholar 

  46. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–96.

    Article  CAS  Google Scholar 

  47. Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003;21(7):1214–22.

    Article  CAS  PubMed  Google Scholar 

  48. Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol. 2001;19(2):425–31.

    Article  CAS  PubMed  Google Scholar 

  49. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003;21(16):3133–40.

    Article  CAS  PubMed  Google Scholar 

  50. Atzpodien J, Schmitt E, Gertenbach U, et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer. 2005;92(5):843–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer. 1996;77(12):2560–6.

    Article  CAS  PubMed  Google Scholar 

  52. Aitchison M, Bray CA, Van Poppel H, et al. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial. Eur J Cancer. 2014;50(1):70–7.

    Article  CAS  PubMed  Google Scholar 

  53. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004;363(9409):594–9.

    Article  CAS  PubMed  Google Scholar 

  54. Rassweiler J. Re: ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Eur Urol. 2012;61(1):219–20.

    Article  PubMed  Google Scholar 

  55. Doehn C, Richter A, Theodor RA, Lehmacher W, Jocham D. An adjuvant vaccination with Reniale®; prolongs survival in patients with renal cell carcinoma following radical nephrectomy: secondary analysis of a multicentre phase-III trial. Eur Urol Suppl. 2006;5(2):286.

    Article  Google Scholar 

  56. May M, Brookman-May S, Hoschke B, et al. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother. 2010;59(5):687–95.

    Article  PubMed  Google Scholar 

  57. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008;372(9633):145–54.

    Article  CAS  PubMed  Google Scholar 

  58. Margulis V, Matin SF, Tannir N, et al. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology. 2009;73(2):337–41.

    Article  PubMed  Google Scholar 

  59. Daliani DD, Papandreou CN, Thall PF, et al. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer. 2002;95(4):758–65.

    Article  CAS  PubMed  Google Scholar 

  60. Belldegrun AS, Chamie K, Kloepfer P, et al. ARISER: a randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC—results and implications for adjuvant clinical trials. J Clin Oncol. 2013;31(15_suppl):4507.

    Google Scholar 

  61. Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375(23):2246–54.

    Article  CAS  PubMed  Google Scholar 

  62. Motzer RJ, Haas NB, Donskov F, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol. 2017;35(35):3916–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Chamie K, Donin NM, Klopfer P, et al. Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial. JAMA Oncol. 2017;3(7):913–20.

    Article  PubMed  Google Scholar 

  64. Bex A, Horenblas S, Meinhardt W, Verra N, de Gast GC. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol. 2002;42(6):570–4; discussion 575–6.

    Article  CAS  Google Scholar 

  65. Jonasch E, Tannir NM. Targeted therapy for locally advanced renal cell carcinoma. Target Oncol. 2010;5(2):113–8.

    Article  PubMed  Google Scholar 

  66. Kalman D, Varenhorst E. The role of arterial embolization in renal cell carcinoma. Scand J Urol Nephrol. 1999;33(3):162–70.

    Article  CAS  Google Scholar 

  67. Mohr SJ, Whitesel JA. Spontaneous regression of renal cell carcinoma metastases after preoperative embolization of primary tumor and subsequent nephrectomy. Urology. 1979;14(1):5–8.

    Article  CAS  PubMed  Google Scholar 

  68. Swanson DA, Johnson DE, von Eschenbach AC, Chuang VP, Wallace S. Angioinfarction plus nephrectomy for metastatic renal cell carcinoma--an update. J Urol. 1983;130(3):449–52.

    Article  CAS  PubMed  Google Scholar 

  69. Bakke A, Gothlin JH, Haukaas SA, Kalland T. Augmentation of natural killer cell activity after arterial embolization of renal carcinomas. Cancer Res. 1982;42(9):3880–3.

    CAS  Google Scholar 

  70. Nakano H, Nihira H, Toge T. Treatment of renal cancer patients by transcatheter embolization and its effects on lymphocyte proliferative responses. J Urol. 1983;130(1):24–7.

    Article  CAS  Google Scholar 

  71. Johnson G, Kalland T. Enhancement of mouse natural killer cell activity after dearterialization of experimental renal tumors. J Urol. 1984;132(6):1250–3.

    Article  CAS  PubMed  Google Scholar 

  72. Zielinski H, Szmigielski S, Petrovich Z. Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma. Am J Clin Oncol. 2000;23(1):6–12.

    Article  CAS  Google Scholar 

  73. Robert G, Gabbay G, Bram R, et al. Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol. 2009;55(6):1477–80.

    Article  CAS  PubMed  Google Scholar 

  74. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res. 2008;14(8):2431–6.

    Article  PubMed  Google Scholar 

  75. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev. 2009;35(4):309–21.

    Article  CAS  PubMed  Google Scholar 

  76. Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol. 2009;181(2):518–23; discussion 523.

    Article  CAS  PubMed  Google Scholar 

  77. Jonasch E, Wood CG, Matin SF, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(25):4076–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Cowey CL, Amin C, Pruthi RS, et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol. 2010;28(9):1502–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Abel EJ, Culp SH, Tannir NM, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 2011;59(1):10–5.

    Article  Google Scholar 

  80. Ficarra V, Novara G. Kidney cancer: neoadjuvant targeted therapies in renal cell carcinoma. Nat Rev Urol. 2010;7(2):63–4.

    Article  CAS  PubMed  Google Scholar 

  81. Rini BI, Garcia J, Elson P, et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol. 2012;187(5):1548–54.

    Article  CAS  PubMed  Google Scholar 

  82. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000;75(12):1236–42.

    Article  CAS  PubMed  Google Scholar 

  83. McKiernan J, Simmons R, Katz J, Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology. 2002;59(6):816–20.

    Article  PubMed  Google Scholar 

  84. Huang WC, Elkin EB, Levey AS, Jang TL, Russo P. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes? J Urol. 2009;181(1):55–61; discussion 61–52.

    Article  PubMed  Google Scholar 

  85. Tan HJ, Norton EC, Ye Z, Hafez KS, Gore JL, Miller DC. Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA. 2012;307(15):1629–35.

    Article  CAS  PubMed  Google Scholar 

  86. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011;59(4):543–52.

    Article  PubMed  Google Scholar 

  87. Hellenthal NJ, Underwood W, Penetrante R, et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol. 2010;184(3):859–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Ansari J, Doherty A, McCafferty I, Wallace M, Deshmukh N, Porfiri E. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma. Clin Genitourin Cancer. 2009;7(2):E39–41.

    Article  PubMed  Google Scholar 

  89. Thomas AA, Rini BI, Stephenson AJ, et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol. 2009;182(3):881–6.

    Article  PubMed  Google Scholar 

  90. Silberstein JL, Millard F, Mehrazin R, et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int. 2010;106(9):1270–6.

    Article  PubMed  Google Scholar 

  91. Simmons MN, Ching CB, Samplaski MK, Park CH, Gill IS. Kidney tumor location measurement using the C index method. J Urol. 2010;183(5):1708–13.

    Article  PubMed  Google Scholar 

  92. Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182(3):844–53.

    Article  Google Scholar 

  93. Karakiewicz PI, Suardi N, Jeldres C, et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol. 2008;53(4):845–8.

    Article  PubMed  Google Scholar 

  94. Harshman LC, Srinivas S, Kamaya A, Chung BI. Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol. 2009;6(6):338–43.

    Article  PubMed  Google Scholar 

  95. Bex A, Van der Veldt AA, Blank C, Meijerink MR, Boven E, Haanen JB. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol. 2010;49(4):520–3.

    Article  CAS  PubMed  Google Scholar 

  96. Cost NG, Delacroix SE Jr, Sleeper JP, et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011;59(6):912–8.

    Article  CAS  PubMed  Google Scholar 

  97. Flanigan RC. Debulking nephrectomy in metastatic renal cancer. Clin Cancer Res. 2004;10(18 Pt 2):6335S–41S.

    Article  PubMed  Google Scholar 

  98. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol. 1995;154(1):35–40.

    Article  CAS  PubMed  Google Scholar 

  99. Fisher RI, Coltman CA Jr, Doroshow JH, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med. 1988;108(4):518–23.

    Article  CAS  PubMed  Google Scholar 

  100. Muss HB, Costanzi JJ, Leavitt R, et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol. 1987;5(2):286–91.

    Article  CAS  PubMed  Google Scholar 

  101. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163(2):408–17.

    Article  CAS  PubMed  Google Scholar 

  102. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–40.

    Article  CAS  Google Scholar 

  103. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.

    Article  CAS  Google Scholar 

  104. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.

    Article  CAS  Google Scholar 

  105. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071–6.

    Article  Google Scholar 

  106. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer. 2003;97(12):2995–3002.

    Article  PubMed  Google Scholar 

  107. Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol. 2001;166(1):68–72.

    Article  CAS  PubMed  Google Scholar 

  108. Han KR, Pantuck AJ, Bui MH, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003;61(2):314–9.

    Article  PubMed  Google Scholar 

  109. Motzer RJ, Russo P. Cytoreductive nephrectomy – patient selection is key. N Engl J Med. 2018;379(5):481–2.

    Article  PubMed  Google Scholar 

  110. Manley BJ, Tennenbaum DM, Vertosick EA, et al. The difficulty in selecting patients for cytoreductive nephrectomy: an evaluation of previously described predictive models. Urol Oncol. 2017;35(1):35.e31–5.

    Article  Google Scholar 

  111. Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010;116(14):3378–88.

    Article  Google Scholar 

  112. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.

    Article  CAS  Google Scholar 

  113. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

    Article  CAS  Google Scholar 

  114. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.

    Article  CAS  Google Scholar 

  115. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.

    Article  CAS  Google Scholar 

  116. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–11.

    Article  Google Scholar 

  118. Szczylik C, Porta C, Bracarda S, et al. Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008;26(15_suppl):5124.

    Article  Google Scholar 

  119. Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185(1):60–6.

    Article  PubMed  Google Scholar 

  120. Warren M, Venner PM, North S, et al. A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J. 2009;3(4):281–9.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Singer EA, Srinivasan R, Bratslavsky G. Editorial comment. J Urol. 2011;185(1):66.

    Article  PubMed  Google Scholar 

  122. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5):417–27.

    Article  PubMed  Google Scholar 

  123. Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial immediate vs deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving sunitinib immediate vs deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving sunitinib. JAMA Oncol. 2019;5(2):164–70.

    Article  PubMed  Google Scholar 

  124. Margulis V, Wood CG. Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy? Eur Urol. 2008;54(3):489–92.

    Article  PubMed  Google Scholar 

  125. Bex A, van der Veldt AA, Blank C, et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol. 2009;27(4):533–9.

    Article  CAS  PubMed  Google Scholar 

  126. Lara PN Jr, Tangen CM, Conlon SJ, Flanigan RC, Crawford ED. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. J Urol. 2009;181(2):512–6; discussion 516–17.

    Article  Google Scholar 

  127. Rodriguez Faba O, Breda A, Rosales A, et al. Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma. Eur Urol. 2010;58(2):307–10.

    Article  PubMed  Google Scholar 

  128. Shuch B, Riggs SB, LaRochelle JC, et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 2008;102(6):692–6.

    Article  PubMed  Google Scholar 

  129. Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology. 2008;72(4):864–8.

    Article  PubMed  Google Scholar 

  130. Wood CG, Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer. 2009;115(10 Suppl):2355–60.

    Article  PubMed  Google Scholar 

  131. Patard JJ, Thuret R, Raffi A, Laguerre B, Bensalah K, Culine S. Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma. Eur Urol. 2009;55(1):237–9; quiz 239.

    Article  PubMed  Google Scholar 

  132. Powles T, Kayani I, Blank C, et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol. 2011;22(5):1041–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Plimack ER, Tannir N, Lin E, Bekele BN, Jonasch E. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer. 2009;115(9):1859–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3):232–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Chapin BF, Delacroix SE Jr, Culp SH, et al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011;60(5):964–71.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology/Yale School of Medicine, Yale New Haven Hospital, New Haven, CT, USA

    Alejandro Abello & Patrick A. Kenney

Authors
  1. Alejandro Abello
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick A. Kenney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick A. Kenney .

Editor information

Editors and Affiliations

  1. Professor of Urology, Tufts University School of Medicine, Boston, MA, USA

    John A. Libertino

  2. Associate Professor of Urology, Tufts University School of Medicine, Boston, MA, USA

    Jason R. Gee

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Abello, A., Kenney, P.A. (2020). Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. In: Libertino, J., Gee, J. (eds) Renal Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-24378-4_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-24378-4_24

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-24377-7

  • Online ISBN: 978-3-030-24378-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation